11-Mar-2021 | Market Research Store
The Global Acute Myeloid Leukemia (AML) Therapeutics Market Is Powered By The Rising Incidence And Prevalence Of Acute Myeloid Leukaemia, Leukemia Research & Development Are Driving Acute Myeloid Leukemia (AML) Therapeutics Growth Across The World.
Leukemia is a broad term for a variety of cancers that involve white blood cells (WBC) and the bone marrow. Leukemia is described by a sudden rise in the number of irregular blood cells, known as blasts, resulting in a reduction in the number of stable, completely modified blood cells, resulting in the usual signs of bleeding, anemia, and a high risk of infection. Leukemia may develop in either the myeloid or lymphoid stem cell lines, depending on how genetic and epigenetic mutations affect the migration of pluripotent stem cells to the different lines of mature cells that then enter the bloodstream. Acute Myeloid Leukemia (AML) is the most common leukemia in adults and is a serious condition. According to the American Cancer Society, the average age at which AML is first diagnosed is 64. AML develops rapidly if left un-treated for a few days, and the patient becomes seriously ill within a few weeks. There is no staging procedure for Acute Myeloid Leukemia because of its rapid onset and acute myeloid leukemia (AML). Acute Myeloid Leukemia (AML) therapy has evolved over the past four decades. Acute myeloid leukemia is the second most common form of leukemia in infants (after acute lymphocytic leukemia).
In 2019, demand for the acute myeloid leukemia therapeutics market was projected at around USD 550.0 million, and current and expected developments by 2026 would reach an estimated USD 1,140.0 million. Companies and experts predict around 11.0% growth in the worldwide acute myeloid leukemia therapeutics market in terms of CAGR. With the high incidence and prevalence of acute myeloid leukemia, advances in pharmacology and molecular biology to support drug production, and the resulting rise in the prevalence of related diseases, new treatments are being developed and increasing and the investments, funds, and grants from public-private organizations are expected to fuel the growth of acute myeloid leukemia therapeutics in the upcoming years.
Major companies in the acute myeloid leukemia therapeutics market contain Genzyme Corporation, Ambit Biosciences Corporation, Sunesis Pharmaceuticals Inc., Celgene Corporation, Abbvie Inc., Cephalon Inc., Astellas Pharma Inc, Clavis Pharma ASA, CTI Biopharma Corp, Eisai Co. Ltd, among others. For Instance, in September 2019, Celgene announced Phase 3 success for CC-486 in Acute Myeloid Leukemia maintenance therapy. In July 2018, AbbVie announced that it has applied a supplementary New Drug Application (sNDA) to the FDA for venetoclax in conjunction with low-dose cytarabine (LDAC) or hypomethylating agent (HMA) for the cure of afresh diagnosed patients with acute myeloid leukemia (AML) who are unavailable for intensive chemotherapy.
The demand for acute myeloid leukemia therapeutics is expected to be driven by the region's rising incidence and prevalence of acute myeloid leukemia. To expand their trade reach, companies in the worldwide acute myeloid leukemia therapeutics market are collaborating with regional agencies. Companies are now concentrating on collaborations, introducing new solutions and enhancing their offerings in order to capture more market share. Growing interest among researchers in acute myeloid leukemia therapeutics due to technological advances. Additionally, the advances in pharmacology and molecular biology to support drug production, as well as expanded funding for acute myeloid leukemia therapeutics research & development, rise in awareness of targeted therapies amongst the population are expected to influence the demand for acute myeloid leukemia therapeutics. In addition, the growing investments, funds, and grants by governments, and pharmaceutical organizations are expected to further increase numerous new prospects in the projected timeframe for the growth of the acute myeloid leukemia therapeutics market. Moreover, the acute myeloid leukemia therapeutics industry is expected to be limited by the less production ability for effectual drugs, the drug difficulty approval process, and the adverse side effects of the drugs used in the therapy. However, the rise in the clinical trials, and the high growth opportunities in emerging countries about emerging acute myeloid leukemia therapeutics technologies will pose prime opportunities for the acute myeloid leukemia therapeutics industry in the future.
The acute myeloid leukemia therapeutics market is segmented as a treatment type, end-user, and region. By treatment type segment, the market is segmented into radiation therapy, targeted therapy, chemotherapy, stem cell transplant, and others. By end-user segment, the market is segmented into hospitals, oncology centers, ambulatory care centers, retail drug stores, and others.
Browse the full “Acute Myeloid Leukemia (AML) Therapeutics Market Treatment Type (Radiation Therapy, Targeted Therapy, Stem Cell Transplant, Chemotherapy, and Others), End-User (Clinics, Hospital, Oncology Centers, Retails Drug Stores, Ambulatory Care Centers, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026.” Report at https://www.marketresearchstore.com/market-insights/acute-myeloid-leukemia-therapeutics-market-828547
In terms of geography, North America represents a higher demand for the acute myeloid leukemia therapeutics market followed by Europe. North America is expected to dominate the growth of acute myeloid leukemia therapeutics due to the easy accessibility of diagnosis, and technical advances in the medical industry. The United States has the highest market share. In developed countries, the United States has a one-of-a-kind healthcare infrastructure. The cost of hospitals, on the other hand, is extremely high in the country; however, the government or private insurers cover it. Furthermore, the Asia Pacific region is the most rapidly developing region in the acute myeloid leukemia therapeutics industry. The market is expected to grow due to the rise in the population, increasing awareness about cancer treatment, to name a few reasons. In order to drive the province's demand for acute myeloid leukemia therapeutics, the heavy participation of prominent suppliers of acute myeloid leukemia therapeutics, the investment of private companies in the development and growth of R&D activities are all prepared. In emerging regions such as the Asia Pacific, the demand for acute myeloid leukemia therapeutics is expected to have a positive outlook during the forecast period.
By Region:
About Us:
Market Research Store is a single destination for all types of industries, global, and regional reports. We feature large repository of latest industry reports and market statistics published by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available. Our vast database of reports enables our clients to benefit from expert insights on global industries, products, and market trends.
Contact Us:
Market Research Store
244 Fifth Avenue, Suite N202
New York, 10001, United States
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@MarketResearchStore.com
Website: https://www.marketresearchstore.com